Clinical Trials Training

More information

EFCCA Academy 2020 - Training Certified Patient Experts

We are pleased to announce that our new edition of the EFCCA Academy offering specialized training for IBD patients  will start on  November 18th 2020 via the EFCCA online learning platform.

This training session will be focused on Clinical Trials  It is composed by 3 modules and it will start with the first one called “Clinical Trials basics”.  Professors Séverine Vermeire and Marc Ferrante from Department of Gastroenterology and Hepatology University Hospitals Leuven / KU Leuven in Belgium will introduce the subject to the students who - at the end of the training - will become the Certified Patients trained on Clinical Trials.

Some of the themes they will cover are: the different phases in the development of medicines, the revolution in IBD treatment over the years, the efficacy of clinical trials and the safety also in real-world after drug approval.  Upon completion of all training modules the Certified Patients will share their knowledge among IBD communities in their countries, teach member association representatives on the subject and also to play an active role with regards to cooperation with pharmaceutical companies at national level.

This first class will be represented by 15 IBD patients from 12 countries: Belgium, Bulgaria, Estonia, France, Greece, Israel, Italy, Mexico, Poland, Portugal, Singapore and Spain.

We are very proud to see very high motivation and we are certain the knowledge gained during the course will empower the patients and local communities.

This training programme has been supported by an unrestricted grant from the following sponsors: 






The EFCCA Academy was created in 2018 following the results of several major surveys that highlighted the main unmet needs of the IBD community. Our pilot project was aimed at providing specialized training addressing some of these unmet needs and appointing Certified Patients to raise awareness on IBD. More info about the EFCCA Academy:

For more information  please send an email to:: (and  in copy).